N-phenyl-N-[2]thienyl-acetamide | 19320-17-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-phenyl-N-[2]thienyl-acetamide
• 英文别名: N-Phenyl-N-[2]thienyl-acetamid；N-(thien-2-yl)acetanilide；N-(2-thienyl)acetanilide；N-Phenyl-N-thienylacetamide；N-phenyl-N-thiophen-2-ylacetamide
• CAS: 19320-17-3
• 化学式: C₁₂H₁₁NOS
• 分子量: 217.291
• InChiKey: NSWHPDKDCAZMJE-UHFFFAOYSA-N

物化性质

• 熔点：
  100-101 °C
• 沸点：
  425.6±18.0 °C(Predicted)
• 密度：
  1.226±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  48.6
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2-溴噻吩 在 potassium carbonate 、 N-乙酰苯胺 作用下， 生成 N-phenyl-N-[2]thienyl-acetamide
  参考文献：
  名称：

  Preparation of N-Acetylphenyl-Z-thienylamine

  摘要：

  DOI：

  10.1021/ja01123a071

文献信息

• 3-piperidyl-4-oxoquinazoline derivatives and pharmaceutical compositions comprising the same
  申请人：Japan Tobacco, Inc.

  公开号：US06235730B1

  公开（公告）日：2001-05-22

  3-piperidyl-4-oxoquinazoline derivatives are provided, which is represented by the formula (I): wherein R represents an amino group or a cyclic amino group such as dibenzoazepine, each of which is substituted with a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, or the like, n is an integer of 1 to 3, R3 and R4 independently represents a hydrogen atom, a lower alkyl group, or the like, or a pharmaceutically acceptable salt thereof. Compounds (I) of the present invention have excellent MTP-inhibitory activity. Thus, these compounds not only inhibit formation of LDL that is a cause of arteriosclerotic diseases but also regulate TG, cholesterol, and lipoproteins such as LDL in the blood and regulate cellular lipids through regulation of MTP activity. They can also be used as a new type of preventive or therapeutic agents for hyperlipemia or arteriosclerotic diseases. Furthermore, they can be used as therapeutic or preventive agents for pancreatitis, obesity, hypercholesterolemia, and hypertriglyceridemia.

  提供了3-哌啶基-4-酮喹唑啉衍生物，其化学式表示为(I)：其中R代表氨基或环氨基，如二苯并蒽，每个都被取代或未取代的芳基、取代或未取代的杂环芳基等所取代，n为1至3的整数，R3和R4独立地表示氢原子、较低的烷基或类似物，或其药学上可接受的盐。本发明的化合物(I)具有出色的MTP抑制活性。因此，这些化合物不仅抑制了是动脉粥样硬化疾病原因之一的LDL的形成，而且通过调节MTP活性，还可以调节血液中的甘油三酯、胆固醇和LDL等脂蛋白，并通过调节细胞脂质来调节细胞脂质。它们还可以作为新型的高脂血症或动脉粥样硬化疾病的预防或治疗药物。此外，它们还可以作为胰腺炎、肥胖症、高胆固醇血症和高甘油三酯血症的治疗或预防药物。
• Synthesis and Conformational Analysis of <i>N</i>-Aromatic Acetamides Bearing Thiophene: Effect of Intramolecular Chalcogen–Chalcogen Interaction on Amide Conformational Stability
  作者：Ai Ito、Marino Asato、Yuki Asami、Kazuo Fukuda、Ryu Yamasaki、Iwao Okamoto

  DOI：10.1021/acs.joc.3c00345

  日期：2023.6.2

  The conformations of aromatic amides bearing an N-(2-thienyl) or N-(3-thienyl) group were investigated in solution and in the crystal state. NMR spectral data indicate that the conformational preferences of these amides in solution are dependent not only on the relative π-electron densities of the N-aromatic moieties, but also on the three-dimensional relationship between carbonyl oxygen and the N-aromatic

  在溶液和晶体状态下研究了带有N -(2-噻吩基) 或N -(3-噻吩基) 基团的芳香酰胺的构象。NMR 光谱数据表明，这些酰胺在溶液中的构象偏好不仅取决于N -芳族部分的相对 π 电子密度，而且还取决于羰基氧和N -芳族部分之间的三维关系。比较N -(2-噻吩基) 酰胺和N -(3-噻吩基) 酰胺的构象偏好表明，N的Z构象-(2-噻吩基)乙酰胺通过酰胺羰基和噻吩硫之间的1,5-型分子内S···O=C相互作用稳定。这些化合物的晶体结构与溶液结构相似。N-芳基-N- (2-噻吩基)乙酰胺和N-甲基-N- (2-噻吩基)乙酰胺中1,5-型分子内S···O=C相互作用的稳定能估计约为. 分别为 0.74 和 0.93 kcal/mol。
• 3-PIPERIDYL-4-OXOQUINAZOLINE DERIVATIVES AND MEDICINCAL COMPOSITIONS CONTAINING THE SAME
  申请人：Japan Tobacco Inc.

  公开号：EP0970954A1

  公开（公告）日：2000-01-12

  3-piperidyl-4-oxoquinazoline derivatives are provided, which is represented by the formula (I): wherein R represents an amino group or a cyclic amino group such as dibenzoazepine, each of which is substituted with a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, or the like, n is an integer of 1 to 4, R3 and R4 independently represents a hydrogen atom, a lower alkyl group, or the like, or a pharmaceutically acceptable salt thereof. Compounds (I) of the present invention have excellent MTP-inhibitory activity. Thus, these compounds not only inhibit formation of LDL that is a cause of arteriosclerotic diseases but also regulate TG, cholesterol, and lipoproteins such as LDL in the blood and regulate cellular lipids through regulation of MTP activity. They can also be used as a new type of preventive or therapeutic agents for hyperlipemia or arteriosclerotic diseases. Furthermore, they can be used as therapeutic or preventive agents for pancreatitis, obesity, hypercholesterolemia, and hypertriglyceridemia.

  提供了3-哌啶基-4-氧代喹唑啉衍生物，由式(I)表示： 其中 R 代表氨基或环状氨基，如二苯并氮杂卓，它们各自被取代或未被取代的芳基、取代或未被取代的杂芳基或类似基团取代，n 是 1 至 4 的整数，R3 和 R4 独立地代表氢原子、低级烷基或类似基团，或其药学上可接受的盐。本发明的化合物（I）具有优异的 MTP 抑制活性。因此，这些化合物不仅能抑制导致动脉硬化疾病的低密度脂蛋白的形成，还能调节血液中的总胆固醇、胆固醇和脂蛋白（如低密度脂蛋白），并通过调节 MTP 活性来调节细胞脂质。它们还可用作高脂血症或动脉硬化疾病的新型预防或治疗药物。此外，它们还可用作胰腺炎、肥胖症、高胆固醇血症和高甘油三酯血症的治疗或预防药物。
• US6235730B1
  申请人：——

  公开号：US6235730B1

  公开（公告）日：2001-05-22